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1. Introduction 
The definition of asthma is constantly being modified and redefined. New knowledge 
derived from molecular biology and applied immunology is very valuable in interpreting 
how the airway becomes diseased. At the same time, new biomarkers useful for monitoring 
patients and detecting inflammatory airway disease are being identified. Currently, patients 
whose condition is included in the spectrum of inflammatory airway diseases may be 
reassessed and placed into subgroups so that the biotypes, or endotypes (disease) and 
phenotypes (patients), form new paradigms to delineate and integrate applied knowledge to 
this complex and heterogeneously-expressed disease. The definition of asthma and different 
ways of understanding the disease undergo constant review. 
2. Asthma defined as an inflammatory airway disease 
The definition of asthma may be established using a set of characteristics that are clinical 
(recurrent episodes of wheezing and dyspnea), pathophysiological (variability in airflow), 
or immunological (chronic inflammation) (Global Initiative for Astma [GINA], 2009; British 
Thoracic Society Scottish Intercollegiate Guidelines Network [BTSSIGN], 2008). They may 
be found in patients or heterogeneous groups of patients who share these symptoms to a 
greater or lesser extent. Depending on the emphasis placed on a more specific predominant 
feature of airway dysfunction, the ‘nominalist’ view of the concept of asthma is more 
relevant. On the other hand, if several features are examined together to make the diagnosis, 
the more 'essentialist' aspect of the specific airway disease stands out [GINA, 2009; BTSSIGN 
2008]. Thus, both definitions must be kept in mind when dealing with asthma, and 
determining an objective system of measurement for the quantifiable aspects that that make 
up either definition is required [Hargreave & Nair, 2009]. For decades, different methods to 
quantify and measure the various components of asthma (symptoms, spirometry, maximum 
peak flow, bronchial provocation) have been used in situations of good health or illness, 
highlighting the complexity involved in studying, functionally, both the normal and altered 
airway. Not all the defining characteristics of asthma are present in all patients; moreover, 
they vary greatly and are often irregular in a single patient. The therapeutic response may 
also be different depending on the specific pathophysiological characteristics that are 
predominately found [Lotvall et al., 2011]. Therefore, the classification of asthma severity by 
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daily medication regimen and response to treatment, as well as the different strategies and 
recommendations for managing patients with difficult to control asthma are essentially 
needed in clinical practice [Holgate & Polosa, 2006]; otherwise they are limited. New 
methods based on statistical physics and fluctuation analysis can be a new strategy for 
assessing and predicting the risk of progression of asthma [Frey & Suki, 2008], but 
monitoring of airway diseases also requires focus on foundations of the modern biology. 
Therefore, the application of new technological advancements and the disciplines applied to 
the study of inflammation, as well as the incorporation of new markers for diagnosis and 
the monitoring of patients affected by asthma, inspires optimism in the challenge to find a 
better conceptual understanding of asthma using a dynamic approach that continuously 
changes and at the same time is more significant than that achieved by mere verification.  
In this chapter, specific aspects of the new contributions to the monitoring of asthma and the 
new research using defined groups of patients to study interrelated heterogeneous aspects 
of asthma will be described and discussed. These new contributions have modified the 
approach to grouping and reclassifying characteristics that are clinical, pathophysiological 
and biological as a whole, and allow for a new definition of asthma in terms of 'phenotypes' 
and 'endotypes' [Anderson, 2008a; Wenzel, 2006]. Although the addition of these new terms 
to the definition of asthma may be seen as a conceptual breakthrough, caution must be 
exercised. For example, new biological knowledge about the pathogenic understanding of 
inflammatory airway disease (IAD) requires further investigation in many aspects, 
including how it differs from phenotypes in chronic obstructive pulmonary disease (COPD) 
[Barnes, 2008], as well as in children [Spycher, 2010]. Hence, a major challenge in the field of 
respiratory disease today is how to adapt the definition of asthma to new scientific 
developments. The verification of objective 'biotypes', in terms of the development of 
asthma and the patients in whom they are observed, is an important conceptual advance, 
provided better clinical management for each patient is achieved so that the relative 
uniqueness of each patient with asthma can be better understood, both by the physician and 
the patients themselves. However, in order to define 'phenotypes' specific to patients or 
subgroups of patients in addition to the specific pathogenic 'endotypes' that identify them 
(in other words, how asthma patients become ill), it is necessary to thoroughly identify their 
defining characteristics. They must therefore be measured and grouped biologically and 
clinically in a differentiated way, even if certain aspects of the illness are the same [Lotvall et 
al., 2011; Moore et al., 2010].  
Today's objective biological measures and markers used to better understand these biotypes 
are the central focus of this chapter. 
3. Monitoring the airway and monitoring asthma in particular 
There are a number of methods available for identifying different aspects related to the 
natural evolution of IAD. The contribution of each aspect is determined by providing 
appropriate measures and robust parameters that meet consistent methodological 
determinants, such as the standardization of the method used, the availability of reference 
values, the reproducibility of findings, and above all the application of research findings to 
clinical practice and the global management of patients whose situation is well-defined as 
well as homogeneous patients or groups of subjects. Not all biological measures studied in 
recent years have managed to become routinely added as a parameter with clinical value in 
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the management of patients. Furthermore, those used routinely provide specific and limited 
information only. Therefore, current research being conducted focuses more on the 
inflammatory aspects of the lung, rather than the classical or clinical function, because it is 
the central pathogenic mechanism of the disease in the airway [Fabbri et al., 2005]. Severity 
and control disease assessment requires a multidimensional practical approach including an 
inflammatory view, as was previously confirmed by some authors [Fitzpatrick et al. 2011a; 
Haldar et al., 2008]. 
Technological advancements brought about by modern molecular biology and innovative 
micron analysis technology applied to the study of inflammation and the pathways of 
oxidative, lipid, or nitric stress, for example, can allow for a better identification and 
definition of new parameters, inflammatory profiles, and biomarkers that are more sensitive 
and specific for predicting the state of progression of IAD, differences in poor outcomes, and 
the type of anti-inflammatory treatment best suited to manage a particular patient or patient 
group. 
This section briefly discusses the most relevant parameters used in clinical practice for the 
monitoring of asthma, especially the most recent parameters that contribute greatly to the 
overall management of patients and other more promising parameters, from the perspective 
derived by direct measurement and monitoring of inflammatory activity. 
3.1 Global systems of measurement for airway disease  
From a clinical point of view, patients are typically monitored through the measurement of 
the symptoms present, questionnaires on the degree of control of the disease [Curtis et al., 
1997] or the impact on quality of life related to health [Juniper et al., 2004], 
pathophysiological parameters such as the degree of bronchial obstruction [FEV1 or PEF] 
[Miller, 2005], and variability [Reddel, 2006] or the degree of bronchial hyper-reactivity, both 
specific and nonspecific [Anderson, 2008b, Cockcroft & Davis 2006; Crapo et al., 2000; Sont 
et al., 1999; Sterk et al., 1993]. Each of these are more or less direct methods of measuring the 
clinical impact of inflammatory diseases of the airways, providing complementary 
information to diagnostic and therapeutic management [Fuhlbrigge, 2004; Gibson & Powell, 
2004; Taylor et al., 2008] and, to a lesser degree, clinical interpretation [Frey & Suki, 2008]. 
They have become absolutely necessary and indispensable for the classification of the 
patient's and establishment of control disease. In terms of study, testing of the whole 
response of the total airway implies knowing several pathogenic mechanisms of disease 
[Bousquet et al., 2000; Leuppi et al., 2001]. Understanding how control of the severity or 
clinical evolution of the disease is developed retains some specific limitations that result in 
advantages and disadvantages. For example, the main advantage of studying bronchial 
hyper-responsiveness to histamine or methacholine challenge is the high negative predictive 
value of the test [Luks et al., 2010]. On the contrary, its presence and the severity observed 
indicate functional impairment of the airway.  This may be interpretable in either a 
physiological (dysfunction, with or without an associated inflammatory basal profile) or 
pathological context (chronic inflammation, injury, mucosal or submucosal remodelling), 
which may or may not be modified by treatment once established [Hargreave et al., 1981; 
Rosi et al., 1999; Sont et al., 1999; van Essen-Zandvliet et al., 1994]. Recent advances in the 
clinical use of substances, such as adenosine or mannitol, provide additional data on the 
association between bronchial hyper-responsiveness, as measured by these indirect stimuli, 
and markers of inflammation [Polosa et al., 2000; Rutgers et al., 2000].  
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Other findings arising from the current radiological spectrum of diseases of the airway also 
provide useful data to study dynamic airway inflammation, expressed as the degree of 
trapped air and bronchial wall thickness [Gupta et al., 2010].  
It is therefore possible to say that although the parameters and measurements discussed in 
this section can be applied to both asthma and COPD in order to achieve better clinical 
management, its meaning and clinical interpretation are often heterogeneous or variable 
depending on the patient, the therapy administered at the time of measurement, and the 
spectrum of IADs identified in the subject, both initially and over time [Avital et al., 1995; 
Dima et al., 2010]. Discrimination of all the spectrum of obstructive airway diseases is the 
goal to achieve at present time.   
3.2 Direct systems of injury and repair measurement in pulmonary biology 
The pathology of the airway has a clearly inflammatory pathophysiological basis, although 
the role this plays, both in the short term and in the long term, in the biological continuum 
of integrity, dysfunction, injury, and repair continues to undergo constant research. 
Traditionally, the gold standard in inflammatory activity has been to use various 
measurements and markers, both inflammatory and those of oxidative stress, obtained 
invasively by bronchial biopsy and bronchoalveolar lavage [Bergeron et al., 2007; Brasier et 
al., 2010; Hallstrand et al., 2011]. Although various parameters and histological patterns of 
inflammation have been identified with these techniques, many of them are shared by the 
anatomopathological spectrum of IAD. This causes ambiguity, both in the various 
pathogenic contexts in which pathophysiological interpretation is difficult and, 
consequently, non-pathognomonic situations in which discrimination regarding asthma or 
COPD occurs. Only some of these findings have demonstrated applicability to clinical care 
and a certain ability to differentiate or discriminate between the inflammatory pathogenic 
states of an underlying pathologic lesion, as in the study of bronchial remodelling [Sont et 
al., 1999; Sont et al., 2003], or the prevalence of the cellular profile of bronchial infiltration, 
as in the case of life-threatening asthma [Mauad et al., 2004; Mauad et al., 2008]. 
Furthermore, both techniques also have some significant limitations when carried out 
routinely. The first is that only one compartment of the airway is represented unless both 
procedures are done at the same time. The second limitation is the invasiveness of the 
procedure. This is an obstacle when routinely performed on the patient, despite the fact 
that these methods have been standardized and allow for a better visualization of the type 
of inflammation and anatomical injury caused by IAD in certain patients. They are also 
useful in studying the pathogenic mechanisms involved, as well as classifying and 
identifying the stage of disease [Fabbri et al., 2003; Fabbri et al., 2005; Moore et al., 2011], 
but the requirements of the procedure do not make them suitable for routine monitoring 
of the patient and are therefore generally reserved today for the systematic study of 
inflammation in pulmonary biology research.  
The new semi-invasive methods, such as induced sputum, or non-invasive methods, such as 
the measurement of nitric oxide, condensation, or exhaled temperature, provide new and 
useful data directly from the airway that may be used in the classification of IADs and the 
management of patients [Popov, 2011]. Some markers derived from blood samples can also 
be used in assessing inflammatory disease and its systemic impact. These include eosinophil 
cationic proteins, as well as cationic peroxidase and leucotriens [Koh et al., 2007; 
Rabinovitch, 2007], but other novel systemic blood biomarkers are also promising [Verrills 
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et al., 2011]. The most important contributions of non-invasive methods currently used to 
measure inflammation of the airway and the most promising research being carried out 
with new applied technologies in molecular biology and immunology are discussed below. 
3.2.1 Induced sputum 
This semi-invasive technique is used to obtain a representative sample of bronchial 
secretions in the airway. Some methodological variations in the induction procedure may 
produce samples from a more central or peripheral compartment of the airway, providing 
versatility in IAD screening in terms of both central and peripheral orientation. This is 
characterized as such because the differential inflammatory profile obtained is reproducible 
and can be correctly interpreted in a clinical context. However, this is not the case in the 
study of the various markers of inflammation and oxidative stress obtained from the 
supernatant, which have strict methodological considerations and limitations in the 
interpretation of results [Nicholas, 2009]. Bearing this in mind, induced sputum has become 
the gold standard non-invasive method for measuring bronchial cell inflammation and for 
certain soluble markers that are identifiable and of specific dilution [Bakakos, 2011; 
Djukanovic 2004]. The standardization of the method and procedure, adequate safeness of 
the technique, good toleration by the patient, ease of use, and the obtainment of reference 
values have made it an essential technique in the study of complex patients who require the 
characterization of the bronchial inflammatory pattern in order to be managed correctly 
[Djukanovic, 2002]. The current characterization of the endotypes and phenotypes of 
patients with inflammatory airway disease, based on inflammatory cell patterns [Balzar et 
al., 2011; Haldar et al., 2008], and the combination of different biomarkers, such as those 
derived from 'esputoma' [Gray et al., 2008; Nicholas, 2006] and oxidative stress [Louhelainen 
et al., 2008a; Louhelainen et al., 2008b], 15-lipoxygenase pathway [Chu, et al., 2002], 
gluthation oxidation [Fitzpatrick et al., 2011b] or genetics and protein identification [Baines 
et al., 2011; Hastie et al, 2010] make sputum an indisputable protagonist in the new 
definition of phenotypes, the classification of patients with asthma and COPD [Fabbri et al., 
2003; Fatj et al., 2009; Louis et al., 2002; Wang et al., 2011], the therapeutic management of 
these patients, the prediction of therapeutic response [Green et al., 2002; Jayaram et al., 2006, 
Caramori et al., 2005], and the evaluation of efficacy in the most recent anti-inflammatory 
molecules [Haldar et al, 2009; Pavord et al. 2009, van Rensen et al. 2009]. Currently, new 
techniques in molecular biology may be applied to the study of sputum in order to study the 
expression shown in the cellular response of certain subtypes of cell lines, as found for 
example, by studying toll-like cell receptors or local innate immunity measured by flow 
cytometry [Lay et al, 2011], or those derived from cell cultures [Bettiol et al., 2002], the 
cellular response to markers of cell migration [Dent et al., 2004], or even those obtained from 
the analysis of proteomics traces or esputoma [Park & Rim, 2011; Nicholas & Djukanovic, 
2009], as well as the genome [Baines et al., 2011; Bisgaard et al., 2011]. 
3.2.2 The exhaled fraction determined singularly or in combination 
The use of exhaled markers capable of reflecting a clinically useful measurement of the 
inflammation and oxidative stress present in the airway currently involves bronchial nitric 
oxide (NO) as the main marker [Barnes et al., 2010]. This measurement is reproducible and 
the method has been standardized [ATS/ERS, 2005]. Because its concentration is dependent 
on the flow and the source of production, a compartmental model of alveolar or bronchial 
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origin of exhaled nitric oxide has been developed in order to study of the origin of the 
alteration and the lung injury, situating it at a more central or peripheral level in the airway 
[Puckett et al., 2010]. This model allows the production variability within the spectrum of 
IAD and the anti-inflammatory modulation produced by the therapy administered to be 
studied in depth. While this method is certainly advantageous when carrying out clinical 
monitoring within a timeframe because of its non-invasivity, it may only be used in 
certain patients, i.e. those in whom the main source of NO has been identified as a clearly 
modifiable and dependent element of the course of inflammation with therapeutic anti-
inflammatory management, or for the screening of type of activated inflammation 
[Anderson et al., 2011]. The use of NO in the research of no homogeneously selected 
patients leads to a clinically confusing interpretation in terms of its identification and 
therefore must be considered limited or biased under these circumstances [Dweik et al., 
2010]. In addition, certain methodological considerations conditioned by the design of NO 
research studies regarding the cut-off used to make a management decision must be taken 
into account during diagnosis and treatment, i.e. conditioning the patient management 
strategy based on the levels of NO [Gibson, 2009; Quaedvlieg et al., 2009; Schleich et al., 
2009; Schneider et al., 2009]. 
Other exhaled markers of the bronchial airway, such as the detection of carbon monoxide 
and other volatile hydrocarbon compounds, products of lipid peroxidation, have also 
been studied [Antczak et al., 2011]. However, a definitive standardization of methods for 
immediate application in a clinical context has not been achieved. Similarly, the 
measurement of exhaled temperature increase at the start of breathing with regard to the 
reference point marked during the entire period of measurement of the increase is 
associated with the presence of active inflammation and airway remodelling [Paredi, 
2005]. This also occurs with the measurement of bronchial blood flow, estimated by mass 
spectrometry using the Fick principle, and the calculation of the dilution of exhaled 
acetylene [the initial concentration inhaled is known]. Both methods may have their place 
in the spectrum of non-invasive monitoring of bronchial inflammation if the optimal 
exhaled flow is standardized methodologically for the purpose of measurement [Paredi & 
Barnes, 2010]. 
The identification of different volatile compounds produced by oxidative stress, nitrosative 
stress, inflammation and metallic elements, and obtained from the exhaled condensate has 
also been possible through the use of chromatography and mass spectrometry [Corradi et al. 
2007; Corradi et al, 2010]. Some of these compounds may be considered biomarkers in 
clinical practice [Baraldi et al., 2009 Kostikas et al., 2008; Loukides et al, 2011], such as pH 
determination [Kostikas et al., 2011; Antus et al, 2010]. However, it is necessary to simplify 
the instrumentation of the procedure for routine use in clinical practice. The standardization 
of methodology and applicability to clinical practice of other compounds under 
investigation as potential biomarkers has yet to be sufficiently achieved due, among other 
things, to certain limitations, such as contamination of condensate compounds of the mouth 
(especially if concomitant oral inflammation occurs), difficulty in calculating the optimal 
dilution of the selected parameter, or instability, volatility, and interaction of the mixture of 
soluble compounds that can take place during this process [Horvàth et al. 2005]. 
Comparisons with other biomarkers obtained and already standardized are needed to 
establish the utility of the different compounds of exhaled condensate, especially if 
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performed one by one [Baraldi et al., 2009]. However, recent specific phenotypes of asthma 
patients, like aspirin intolerant asthmatics can be identified [Sanak et al, 2011]. 
Calculating the nasal exhaled fraction may be useful for the study and diagnosis of primary 
ciliary dyskinesia and is virtually abolished in this disease [Horváth et al., 2003]. On the 
contrary nasal NO levels are higher in rhinitis [Struben et al., 2006] 
3.2.3 The multiple molecular studies of biological lung samples, or systemic samples, 
significant to pulmonary disease  
Since the detection of a single marker of inflammation or oxidative stress does not identify a 
specific inflammatory disease of the airway as defined today, but rather proves the 
heterogeneity of inflammatory conditions and diseases of the airway, current research on 
biological markers focuses on a combination of identifying patterns of proteins and volatile 
compounds that can be identified by molecular marks or traces they contain. At the 
molecular level, many omic compounds (proteomic, metabolomic, genomic) may be 
identified. Within the field of respiratory medicine, these compounds will remain an enigma 
until the wealth of empirical molecular information is organized and interpreted, free of a 
priori hypotheses, and the subsequent translation to clinical practice can be carried out. Such 
information would have the great advantage of producing a custom 'fingerprint' of 
inflammation during a specific time point in the evolution of the disease process in a 
particular patient. The correct interpretation of molecular information will allow the 
clinician to identify and predict the patient and disease biotypes (phenotype and endotype), 
the severity of the inflammatory process in progress, the clinical evolution, the type of 
treatment to be applied, the response to the therapy administered, and the prognosis for 
each individual patient [Crameri, 2005; Vijverberg et al., 2011]. The new molecular 
application technology based on bioinformatics, cluster analysis, and artificial intelligence 
algorithms that are being developed at present provide all this information for the purpose 
of prediction and interpretation at a biological level. This is useful in understanding the new 
biology of systems integration [Perpiñá, 2010; Scott et al., 2007; Thaler & Hanson, 2005]. The 
following is a description of the research currently being conducted. 
First, chromatography and mass spectrometry have been used to identify hundreds of 
volatile exhaled organic compounds originating from the metabolic pathways involved in 
pulmonary biology. However, their use as biomarkers with a clinical application is still 
under study [Freidrich, 2009]. Secondly, the addition of other specific technology for 
determining the spectrum of metabolites, proteins or organic compounds in different 
biological samples (cellular, fluid, or gas) in blood, sputum, or bronchoalveolar lavage, and 
developed on line, such as the application a multiple set of nanosensors (arrays) or the 
application of high-resolution nuclear magnetic resonance, has achieved rapid progress in 
identifying potential profiles and patterns of disease-specific biomarkers. For example, 
different patterns of compounds originating in breathing and exhaled breath evaluated by 
the so-called electronic nose identify molecules of different size, volume and dipole [Lewis, 
2004]. These patterns have shown good sensitivity and discrimination capabilities for this 
combination and may be as helpful as those already described for the identification of 
certain odours, producing an odoriferous mark or smellprint. This would specifically identify 
the type of inflammation present and could be useful in the differential diagnosis of specific 
IADs [Dragonieri et al., 2007] in addition to the particular diagnostic and therapeutic 
strategies for each patient. 
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4. The future of targeted and individualized biological respiratory therapy 
The new concept of biotypes (endotypes and phenotypes) of IAD is transforming the 
definition of asthma to the point where it will soon be possible to obtain a more accurate 
simplification of what is understood today as asthma in order to better adapt to patient 
management and the clinical reality. However, the definition of asthma that currently exists 
is complex and will remain so, despite continuous modification and rehabilitation, given 
that although the heterogeneity of the IAD is better understood and the subtypes of the 
disease and patient subgroups are better classified, the multifactorial and dynamic aspects 
of the biological responses involved make applying reductionist criteria very difficult. It is 
therefore necessary to maintain a flexible and mentally versatile attitude that is as dynamic 
as biology itself. This attitude will facilitate the understanding of respiratory medicine of the 
future, which in turn will affect therapeutic management. This approach may be considered 
the cornerstone of individualized therapy for respiratory patients. It will aid in the 
progressive incorporation of biopharmaceuticals capable of regulating or altering 
inflammatory pathways, the remodelling process and the smooth muscle response. Both 
strategies are complementary and briefly commented. 
First, the action and biological and immunological mechanisms will modulate the degree of 
response obtained at the molecular level and will result clinically in a very specific action. 
Being able to have these modulating biopharmaceuticals will be crucial and improve the 
quality of life for patients with IAD and asthma [Adock et al., 2008; Casale & Stokes, 2008]. 
However, the availability of these drugs will lead to a major challenge at the clinical level 
that they will be reflected in trying to establish well-defined therapeutic indications to 
ensure safe, efficient, and cost-effective use. Some examples of modulating 
biopharmaceuticals in the context of eosinophilic inflammation that have been used in 
patients with poor control and greater severity of symptoms are those that interfere with the 
biological action of IgE, IL-5 or TNF. The attainment of adequate control and improvement 
of outcome in these patients is a sign of success in the development of new molecules, such 
as the monoclonal antibodies, mepolizumab, etarnercept or omalizumab [Holgate et al, 
2011; Pavord et al., 2010; Pelaia et al., 2011]. Other biological modulating drugs acting at the 
neutrophilic, mast o lymphocite cells or other relevant molecules in the pathways and the 
inflammatory response, are being tested for the purpose of incorporation into the 
therapeutic arsenal available for IAD [Chung & Marwick, 2010, Barnes, 2009]. 
Pharmacogenetics and understanding of innate immunty pathways are promising areas of 
research to discover determined mechanisms and specific molecules to reverse the altered 
inflammatory response [Caramori et al., 2004; Kanagaratham et al., 2011; Gupta & Agrawal, 
2010; Slager, 2010].  
Second, the important thing to considering the therapy of releaving symptoms in the 
asthma clinic course is the understanding of the mechanical obstruction in the airways 
and the air-trapping compensatory consequence [Sorkness et al., 2008]. New long-acting 
smooth muscle relaxant molecules are been incorporated alone or in combination to the 
inhaler therapy [Cazzola et al., 2011; Chung et al., 2009; Kiyokawa  et al., 2011; Postma et 
al., 2011], but recent knowing of the genetics of airway smooth muscle points out a new 
strategies to develop asthma targeted molecules [Hai, 2008]. Another specific therapy 
focus on smooth muscle of the airways, like bronchial thermoplasty, is still under 
evaluation [Thompson et al., 2011]. 
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5. Conclusion 
Inflammatory diseases of the airway, and asthma in particular, are complex and 
heterogenous, both in terms of the biological expression of inflammation they produce and 
in terms of the 'biotypes' (endotypes and phenotypes) that can be objectively translated from 
this condition. New information provided by new technology applied to modern molecular 
biology and immunology requires the current concept and definition of asthma to be 
modified and adapted. The attainment of this important progressive scientific knowledge 
can help to address how and why this condition occurs and may contribute to a better 
understanding of the classification of each asthma patient, the proper diagnosis of the type 
of asthma presented, the monitoring approach, the personalized treatment required, and the 
method to determine prognosis. A wide spectrum of biomarkers is currently being 
incorporated as clinically useful parameters. What remains is to gradually adapt them to 
comprehensive of multidimensional approaches and medical procedures, and establish the 
appropriate indications and clinical applications in respiratory disease. 
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